1. Home
  2. PVL vs SCYX Comparison

PVL vs SCYX Comparison

Compare PVL & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Permianville Royalty Trust Trust Units

PVL

Permianville Royalty Trust Trust Units

HOLD

Current Price

$1.84

Market Cap

57.1M

Sector

Energy

ML Signal

HOLD

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$5.30

Market Cap

51.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PVL
SCYX
Founded
2011
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
57.1M
51.4M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
PVL
SCYX
Price
$1.84
$5.30
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
60.4K
83.3K
Earning Date
03-20-2026
05-06-2026
Dividend Yield
7.43%
N/A
EPS Growth
N/A
61.36
EPS
N/A
N/A
Revenue
N/A
$257,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$608.78
P/E Ratio
$26.85
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.58
$0.57
52 Week High
$2.04
$6.09

Technical Indicators

Market Signals
Indicator
PVL
SCYX
Relative Strength Index (RSI) 58.41 57.53
Support Level $1.73 $4.65
Resistance Level $1.92 $5.56
Average True Range (ATR) 0.04 0.36
MACD 0.00 -0.04
Stochastic Oscillator 64.36 34.87

Price Performance

Historical Comparison
PVL
SCYX

About PVL Permianville Royalty Trust Trust Units

Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production from non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: